Abgenix reports ABX-IL8 psoriasis data

ABGX said that in a 94-patient, double-blind, placebo-controlled Phase IIa study, a 3 mg/kg dose of its ABX-IL8 gave a significant improvement in moderate-to-severe psoriasis based on PASI scores and ...